Metformin


Concise Prescribing Info
Indications/Uses
Type 2 diabetes mellitus.
Dosage/Direction for Use
Adult: PO Treatment: As conventional tab/solution: Initial: 500 or 850 mg bid or tid, gradually increase at intervals of at least 1 week according to response. Max: 3,000 mg/day in 3 divided doses. As extended-release tab: Initial: 500 mg/day with evening meal, increase dose in increments of 500 mg up to Max 2,000 mg/day according to response. Prophylaxis: As extended-release tab: Initial: 500 mg/day with evening meal, gradually increase dose at intervals of 10-15 days, according to response. Max: 2,000 mg/day with evening meal.
Administration
Should be taken with food.
Contraindications
Acute or chronic metabolic acidosis with or without coma, acute conditions which may alter renal function (e.g. dehydration, severe infection, shock), acute or chronic disease-causing hypoxia (e.g. unstable cardiac or respiratory failure, recent MI, shock), acute alcohol intoxication or alcoholism. Severe renal (eGFR<30 mL/min) impairment. Intravascular administration of iodinated contrast agents.
Special Precautions
Patients with risk factors for lactic acidosis, stable heart failure, dehydration, prerenal azotemia. Mild to moderate renal impairment. Hepatic impairment. Children and elderly. Pregnancy and lactation. Not indicated for use in patient with type 1 diabetes mellitus or with diabetic ketoacidosis. Monitoring Parameters Monitor glucose and ketones (urine and blood), fasting blood sugar, haemoglobin A1c at least twice yearly in stable glycaemic control; quarterly if not meeting therapy goals. Monitor renal function prior to initiation of therapy and annually thereafter; haematologic parameters at baseline and annually thereafter; vitamin B12 serum concentration every 2-3 years (prolonged use). Monitor for signs and symptoms of lactic acidosis.
Adverse Reactions
Significant: Vitamin B12 deficiency. Cardiac disorders: Chest discomfort, palpitations, dyspnoea. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, flatulence, heartburn/dyspepsia, abdominal distention, abnormal stools, constipation. General disorders and administration site conditions: Asthenia, flu-like symptoms, malaise. Hepatobiliary disorders: Cholestatic, hepatocellular, mixed hepatocellular liver injury. Musculoskeletal and connective tissue disorders: Myalgia, chills. Nervous system disorders: Taste disturbance, headache. Psychiatric disorders: Increased somnolence. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection. Skin and subcutaneous tissue disorders: Nail disease, rash. Vascular disorders: Flushing.
Potentially Fatal: Lactic acidosis.
Drug Interactions
Increased risk of hypoglycaemia with insulin and insulin secretagogues (e.g. sulfonylurea). Increased risk of lactic acidosis with carbonic anhydrase inhibitors (e.g. acetazolamide, dichlorphenamide), NSAIDs, and antihypertensive agents (e.g. ACE inhibitors). Increased plasma concentration and reduced clearance with OCT2 inhibitors (e.g. cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole).
CIMS Class
ATC Classification
A10BA02 - metformin ; Belongs to the class of biguanides. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on metformin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in